HAVANA, Cuba, Nov 28 (ACN) Cuba announced the setting up of the BioCubaFarma Biotechnological and Pharmaceutical Industry Group from the merger of scientific centers, with the aim of producing medications, equipment and services for the population and for exports. The initiative comes after a decision by the Cuban Council of State, through decree 307, dated November 27, 2012.
The new conglomeration of 38 companies also includes entities with the Quimefa entrepreneurial group and it was conceived following the technical and scientific level achieved by the country.
The decision to set up the new entity is in tune with the economic and social guidelines approved by the 6th Congress of the Cuban Communist Party about the consolidation of the pharmaceutical and biotechnological industry as one of the country’s areas with higher export capacity, and able to introduce new products into the local market to replace imports.
The new group will be headed by Doctor Carlos Manuel Gutierrez Calzado, who was the director of the Havana-based National Scientific Research Center.
Over the years, Cuba has developed medications to deal with a wide range of illnessed including lung uterine and colon cancer, prostate cancer, diabetes, alzheimer’s disease and many other common diseases.
The CIGB-300, a synthetic antitumor peptide-based drug intended to treat uterine cancer has received the Special Award granted by the Latin American Society of Pharmacology, while the Cuba-made medication Heberprot-P, used in the treatment of diabetic foot ulcers, has received positive reviews in clinical trials in Europe.
A new Cuban vaccine against chronic Hepatitis B (Nasvac) was one of the innovations introduced during the International Congress on Biotechnology in Havana last March and Cuban and Chinese specialists are coordinating the clinical evaluation in China of a Cuban therapeutic vaccine —Cimavax-EGF— against advanced lung cancer, which was developed at Havana’s Center of Molecular Immunology and which has had favorable statistic results during clinical trials in the Caribbean nation.
In addition, the efficiency of an allergy vaccine against bronchial asthma, among other pathologies, is being tested by Cuban scientists working at Havana’s National Center of Bio-Products (BIOCEN).